Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 14 of 15

 
 

Krystal Biotech (NASDAQ:KRYS)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
8 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$196.75 (6.8% Upside)

About Krystal Biotech

Krystal Biotech logoKrystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/11/2024Stifel NicolausBoost Price TargetBuy ➝ Buy$204.00 ➝ $220.00
8/30/2024William BlairUpgradeStrong-Buy
8/29/2024Cantor FitzgeraldReiterated RatingOverweight
8/28/2024HC WainwrightBoost Price TargetBuy ➝ Buy$200.00 ➝ $221.00
8/12/2024Evercore ISIBoost Price TargetOutperform ➝ Outperform$201.00 ➝ $206.00
8/6/2024CitigroupReiterated RatingBuy ➝ Neutral$195.00 ➝ $204.00
8/5/2024Chardan CapitalBoost Price TargetBuy ➝ Buy$153.00 ➝ $208.00
8/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
5/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00
4/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$200.00
 

Ex-Wall Street CEO reveals “Millionaire-Maker” Superdrug (Ad)

Science Magazine called it the "breakthrough of the year"... With projections of 8,966% growth in the next four years.

Click here for our #1 "Retirement Window" Stock >>>